Letter

Deciding which selective serotonin reuptake inhibitor to prescribe

BMJ 1995; 311 doi: 10.1136/bmj.311.7020.1641a (Published 16 December 1995)
Cite this as: BMJ 1995;311:1641.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Anthony J Cleare, Lecturer in liaison psychiatry Department of Psychological Medicine, Institute of Psychiatry
  1. London SE5 8AZ

    EDITOR,--Recent articles have debated the relative costs of selective serotonin reuptake inhibitors for depression in relation to their tolerability and efficacy.1 2 I M Anderson and B M Tomenson raise the point that cost-benefit analyses should include real life prescribing situations rather than the atypical situations found in short clinical trials.1

    Intense media publicity and debate have been given to …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular